Additive benefits of tiotropium in COPD patients treated with long-acting β2 agonists and corticosteroids

Respirology

Volumn 11, Issue 5, 2006, Pages 598-602

  Perng, Diahn Warng ^a,b   Wu, Cheng Che ^a   Su, Kang Cheng ^a   Lee, Yu Chin ^a,b   Perng, Reury Perng ^a,b   Tao, Chi Wei ^b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHENG HSIN REHABILITATION MEDICAL CENTER   (Taiwan)

Author keywords

Bronchodilator response; COPD; Long acting 2 agonists; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LONG ACTING DRUG; TIOTROPIUM BROMIDE;

ADD ON THERAPY; AGED; ARTICLE; BRONCHODILATATION; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; INSPIRATORY CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MEDICAL ASSESSMENT; MEDICAL NEBULIZER; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RESIDUAL VOLUME; SAINT GEORGE RESPIRATORY QUESTIONNAIRE SCORE; SAMPLE SIZE; SCORING SYSTEM; THERAPY EFFECT; TREATMENT RESPONSE;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; INSPIRATORY CAPACITY; IPRATROPIUM; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; VITAL CAPACITY;

EID: 33746879882     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.00889.x     Document Type: Article

References (24)

1. National Institutes of Health. National Heart Lung, and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO, workshop report. NIH publication no. 2701, March 2001.
2. Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-56.
3. Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81.
4. Disse B, Speck GA, Rominger KL et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64: 457-64.
5. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
6. Cazzola M, Centanni S, Santus P et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir. Med. 2004; 98: 1214-21.
7. Cazzola M, Di Marco F, Santus P et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. 2004; 17: 35-9.
8. Perng DW, Wu CC, Su KC et al. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility. Lung 2006 (in press).
9. Barr JT, Schumacher GE, Freeman S et al. American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin. Ther. 2000; 22: 1121-45.
10. Dales RE, Spitzer WO, Tousignant P et al. Clinical interpretation of airway response to a bronchodilator. Epidemiologic considerations. Am. Rev. Respir. Dis. 1988; 138: 317-20.
11. Calverley PM, Burge PS, Spencer S et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-64.
12. American Thoracic Society. Standardization of spirometry, 1994 update. American Thoracic Society. Am. J. Respir. Crit. Care Med. 1995; 152: 1107-36.
13. van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 2005; 26: 214-22.
14. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
15. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch. Intern. Med. 1999; 159: 156-60.
16. The COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997; 112: 1514-21.
17. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105: 1411-19.
18. Cazzola M, Noschese P, Salzillo A et al. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir. Med. 2005; 99: 524-8.
19. Tennant RC, Erin EM, Barnes PJ et al. Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr. Opin. Pharmacol. 2003; 3: 270-6.
20. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441-9.
21. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832-40.
22. Rutten-van Molken M, Roos B, Van Noord JA. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999; 54: 995-1003.
23. Osman IM, Godden DJ, Friend JA et al. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52: 67-71.
24. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am. J. Respir. Crit. Care Med. 1997; 155: 1283-9.